###begin article-title 0
Interplay of Fli-I and FLAP1 for regulation of beta-catenin dependent transcription
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
beta-catenin mediates Wnt/wingless signaling and transcriptional activation by lymphocyte enhancer binding factor 1/T cell factor (LEF1/TCF) proteins with the assistance of multiple coregulators, including positive cofactors like p300/CBP and negative cofactors like HDACs. We previously demonstrated that a developmentally essential protein, Flightless-I (Fli-I), serves as a coactivator for nuclear receptor-mediated transcription. To further understand the action mechanism of Fli-I, we investigated the functional roles of Fli-I and Fli-I leucine rich repeat associated protein 1 (FLAP1) in transcriptional activation by beta-catenin and LEF1/TCF. beta-catenin-dependent transcription was activated by exogenous FLAP1 but inhibited by Fli-I. Reduction of endogenous FLAP1 levels compromised transcriptional activation by LEF1/TCF, beta-catenin and the p160 coactivator GRIP1. FLAP1 interacted directly with beta-catenin, GRIP1 and p300 and enhanced their activity. Furthermore, FLAP1 was strongly synergistic with p300 in supporting transcriptional activation by beta-catenin and LEF1/TCF, but Fli-I disrupted the synergy of FLAP1 with p300 and beta-catenin. Thus the opposing effects of Fli-I and FLAP1 may be a key regulatory mechanism for beta-catenin and LEF1/TCF-mediated transcription and thus for Wnt signaling, and some mutations of Fli-I may result in developmental defects, such as the flightless phenotype of Drosophila, by causing dysregulation of the Wnt/beta-catenin pathway.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 126 127 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 128 129 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 236 237 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 450 451 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 912 913 894 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 1211 1212 1184 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 1213 1214 1186 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 1223 1224 1196 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 1255 1256 1228 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 1257 1259 1230 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 1272 1274 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 1367 1368 1337 1338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 1369 1371 1339 1341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 1372 1374 1342 1344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 118 124 <span type="species:ncbi:9606">humans</span>
beta-catenin is an essential factor in various developmental and pathological processes of animals from Drosophila to humans (1,2). beta-catenin has important roles in regulating cell-cell contacts and actin cytoskeleton configuration (3). beta-catenin is also involved in the Wnt/wingless signaling pathway and acts as a coactivator for the lymphocyte enhancer binding factor 1/T cell factor (LEF1/TCF) family of transcriptional activator proteins (1). Binding of Wnt ligand to a Frizzled receptor leads to the activation of Disheveled protein and the inhibition of kinase activity of the glycogen synthase kinase-3B/Axin/adenomatous polyposis coli complex. This prevents phosphorylation of beta-catenin and thus results in stabilization of beta-catenin in the cytoplasm. The accumulated beta-catenin protein translocates into the nucleus, where it binds to and enhances transcriptional activation by LEF1/TCF (4). The beta-catenin-LEF1/TCF complex regulates the expression of the c-Myc and cyclin D1 genes among others. beta-catenin and LEF1/TCF dependent gene expression is regulated by the interplay of various coregulators. Positive transcription regulators for beta-catenin and LEF1/TCF include p300/CBP (5-7), BRG1 (8), the p160 coactivator GRIP1 (9,10) and CARM1 (11). Negative regulators of beta-catenin and LEF1/TCF include HDACs, CtBP, Groucho and Chibby (4,12-16).
###end p 4
###begin p 5
###xml 228 230 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 231 233 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 234 236 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 354 355 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 356 357 347 348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 358 359 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 360 362 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 995 997 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 1108 1110 1099 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 1111 1113 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 1114 1116 1105 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 1362 1364 1350 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 1365 1367 1353 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 1368 1370 1356 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 1462 1464 1450 1452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
Interestingly, the beta-catenin mediated pathway has crosstalk with nuclear receptor (NR) dependent pathways. beta-catenin interacts directly with androgen receptor (AR) and acts as a coactivator for AR-dependent transcription (10,17,18). Some common coactivators, including beta-catenin and p300, mediate transcriptional activation by LEF1/TCF and NRs (5-7,9-11). These coactivators enhance transcription activation by remodeling chromatin and by direct interaction with other components of the transcription machinery. Many coactivators form complexes that synergistically enhance transcriptional activation. For example, the three p160 coactivators (SRC1, GRIP1/TIF2, pCIP/ACTR/AIB1/RAC3/TRAM1) interact with other coactivators like the protein acetyltransferase p300 and coactivator associated arginine methyltransferase 1 (CARM1) to regulate histone acetylation and methylation. The C-terminal activation domain (AD) 2 of GRIP1 binds to CARM1 and the adjacent domain AD1 binds to p300/CBP (19). In addition, the N-terminal AD3 domain of GRIP1 interacts with Fli-I (Flightless-I) and other coactivators (18,20,21). Many of these components cooperate synergistically as coactivators for various DNA-binding transcription factors. For example, CARM1 and p300 synergistically enhance the activity of NR, beta-catenin, p53, NFkB and other transcription factors (11,22-24). Similarly, CARM1 and Fli-I show synergy in the activation of NR-dependent transcription (20)
###end p 5
###begin p 6
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 893 895 893 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 1321 1323 1321 1323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 1324 1326 1324 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 1556 1558 1556 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 1777 1779 1777 1779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 1966 1968 1966 1968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 1969 1971 1969 1971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">32</xref>
###xml 2236 2238 2236 2238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 380 384 <span type="species:ncbi:10090">mice</span>
###xml 521 526 <span type="species:ncbi:9606">human</span>
###xml 876 881 <span type="species:ncbi:10090">mouse</span>
###xml 886 891 <span type="species:ncbi:9606">human</span>
###xml 1033 1038 <span type="species:ncbi:9606">human</span>
###xml 1084 1089 <span type="species:ncbi:9606">human</span>
###xml 1938 1943 <span type="species:ncbi:4932">yeast</span>
###xml 1988 1993 <span type="species:ncbi:10090">mouse</span>
###xml 2038 2043 <span type="species:ncbi:9606">human</span>
###xml 2123 2151 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Previously, we identified Fli-I as a CARM1 binding protein and as a coactivator for NR-dependent transcription (20). Fli-I was originally characterized as a developmentally essential protein in Drosophila (25). Severe mutations or homozygous knock-out of the gene encoding Fli-I lead to impaired cellularization and gastrulation of Drosophila embryos and early embryonic death in mice (26). Even mild mutations of Fli-I in Drosophila cause defects in the development of flight muscles and a loss-of-flight phenotype. The human Fli-I gene is located in a region of chromosome 17p which is associated with Smith-Magenis syndrome, a genetic disease causing developmental and behavioral abnormalities (27). In spite of the developmental significance of Fli-I, its biochemical roles remain to be further elucidated. Fli-I has a highly conserved protein structure among Drosophila, mouse and human (25), with a leucine rich repeat (LRR) motif at the N-terminus and a gelsolin-like domain in the C-terminal region. The C-terminal region of human Fli-I has 31% identity and 52% similarity to human gelsolin, which is a member of an actin-binding protein family. The gelsolin-like domain of Fli-I interacts with actin and the actin-like protein BAF53 (Brg1 associated factor 53), which are both components of the Swi/Snf complex (20,28). In cultured cells Fli-I can be in the nucleus or associated with actin in the cytoskeleton, depending on the serum levels and growth conditions, suggesting multiple roles for Fli-I in transcription and cytoskeleton regulation (29). As with the LRR-motifs of other proteins, the LRR domain of Fli-I consists of 16 tandem LRRs. Proteins with LRR domains have diverse cellular localization and functions such as transcription and signal transduction (30). LRR domains often function in protein-protein interactions. To understand the roles of Fli-I LRR, two independent groups identified interacting proteins by yeast two-hybrid screening (31,32). These include mouse Fli-I LRR associating protein 1 (FLAP1) and human LRR Fli-I interacting proteins 1 and 2 (LRRFIP1 and 2). A related protein, the human immunodeficiency virus TAR RNA interacting protein (TRIP), was isolated by another group of investigators (33). Interestingly, all of these proteins, FLAP1, LRRFIP1 and 2 and TRIP have similar sequences and predicted structure rich in alpha-helices and coiled-coils. However, the biochemical functions of these proteins remain obscure.
###end p 6
###begin p 7
In this study, we investigated the functional roles of Fli-I and FLAP1 in regulating transcriptional activation by beta-catenin and LEF1/TCF. FLAP1 is a key activator, cooperating synergistically with p300 to mediate transcriptional activation by beta-catenin and LEF1/TCF. This synergy of FLAP1 and p300 was negatively regulated by Fli-I. This study suggests that the interplay of Fli-I and FLAP1 may be one of the important regulation mechanisms of the beta-catenin dependent, Wnt signaling pathway.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Plasmids
###end title 9
###begin p 10
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">32</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 599 600 590 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 601 603 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 642 644 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
A FLAP1 expression vector, pCMV-FLAP1 was obtained from Dr Helen L. Yin (University of Texas Southwestern Medical Center) (32). The other constructs were described in previous publications as follows: coactivator expression vectors: pSG5-HA.GRIP1, pSG5-HA.CARM1, pCMV-p300, pSG5.HA (24); Fli-I expression vectors: pcDNA-Fli-I, pSG5-flag.LRR and pSG65-flag.Gelsolin (20); GST-protein expression vectors: pGEX4T-KIX, pGEX4T-GBD (34); pGEX4T-GRIP1N, pGEX4T-GRIP1M, pGEX4T-GRIP1C, pGEX4T-ER (24); pGEX-beta-catenin, pGEX-LEF1, TOP-flash, pGL3OT-luc, pSG5-HA.beta-catenin, pSG5-HA.LEF1, pM-beta-catenin (9,11); pM-GRIP1N, pM-GRIP1M and pM-GRIP1C (19).
###end p 10
###begin title 11
Transfection
###end title 11
###begin p 12
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
293T cells were transfected with plasmids by using F1 Targefect reagent (Targeting Systems) according to the manufacturer's protocol as described previously (20,24). Luciferase activity was measured after 40 h. Results shown are the mean and deviations from mean of two transfected cultures. Luciferase assay data shown are representative of at least three independent experiments.
###end p 12
###begin title 13
GST-pulldown assay
###end title 13
###begin p 14
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 112 128 112 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 157 163 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E.coli</italic>
###xml 112 133 <span type="species:ncbi:511693">Escherichia coli BL21</span>
###xml 157 163 <span type="species:ncbi:110766|species:ncbi:562">E.coli</span>
The procedure for GST-pulldown assays was described previously (20,34) and used GST fusion proteins produced in Escherichia coli BL21 cells. The transformed E.coli cells were induced by IPTG and lysed by sonication. GST-fused proteins were collected by incubation with glutathione Sepharose beads.
###end p 14
###begin title 15
Co-immunoprecipitation and immunoblot
###end title 15
###begin p 16
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 62 64 62 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
The co-immunoprecipitation assay was described previously (20,24). One microgram of anti-flag antibody (Sigma) and protein A/G agarose were incubated with cell extracts. The immunoprecipitated fractions were washed and analyzed by immunoblot analysis with anti-HA antibody (Roche).
###end p 16
###begin title 17
siRNA
###end title 17
###begin p 18
###xml 40 42 40 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 43 45 43 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 84 89 <span type="species:ncbi:9606">human</span>
siRNA assays were described previously (20,34). siRNAs for FLAP1 (designed from the human LRRFIP1 sequence in GenBank accession no. NM_004735) are as follows. siFLAP1A: (sense) AGCCGGGAGAUCGACUGUUdTdT, (anti-sense) AACAGUCGAUCUCCCGGCUdTdT; siFLAP1B: (sense) GAAACACAUCGGCUUCUGAdTdT, (anti-sense) UCAGAAGCCGAUGUGUUUCdTdT.
###end p 18
###begin p 19
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
Sequences of siRNAs for Fli-I, AIB1 and CARM1 were described previously (20). Transfections were performed by using oligofectamin or lipofectamine 2000 (invitrogen). MCF-7 and 293T cells were used for this assay. FLAP1 antibody (BD Transduction laboratories) was used in immunoblots for detecting endogenous FLAP1 in MCF7 cells.
###end p 19
###begin title 20
RESULTS
###end title 20
###begin title 21
FLAP1 and Fli-I regulate transcription mediated by beta-catenin and LEF1
###end title 21
###begin p 22
###xml 255 264 252 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1A</xref>
###xml 653 654 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 655 657 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
LEF1/TCF-mediated transcription was examined by transfection of the pGL3OT-Luc or TOPflash-luc reporter plasmid (regulated by binding sites for LEF1/TCF) into mammalian cells. Over-expression of beta-catenin activated the TOPflash reporter in 293T cells (Figure 1A, bar 2) and transfection of increasing amounts of FLAP1 expression plasmid led to a dramatic activation of LEF1/TCF-dependent transcription (bars 3-5). In contrast, over-expression of Fli-I did not affect transcription activation by beta-catenin and LEF1/TCF (bars 9-11). GRIP1 also cooperated with beta-catenin to enhance LEF1/TCF-dependent transcription (bars 6-8) as previously shown (9,10).
###end p 22
###begin p 23
###xml 326 335 317 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1B</xref>
###xml 757 759 739 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 946 955 925 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1A</xref>
###xml 999 1008 975 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1B</xref>
###xml 1106 1115 1079 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1B</xref>
To test the effects of FLAP1 and Fli-I on beta-catenin activity in a one hybrid assay, a plasmid encoding GAL4 DBD fused to beta-catenin was transfected along with the GK1-luc reporter plasmid, which is controlled by binding sites for GAL4 DBD. GAL4 DBD fused to beta-catenin enhanced expression of the GK1-luc reporter gene (Figure 1B, bar 2) and co-expression of FLAP1 further enhanced beta-catenin-mediated transcriptional activation (bar 3). Surprisingly, over-expressed Fli-I strongly inhibited beta-catenin activity (bar 4). However, the LRR and gelsolin fragments of Fli-I caused little if any inhibition of beta-catenin-mediated transcription (bars 5 and 6), even though these Fli-I fragments were expressed at higher levels than full length Fli-I (20). This result suggests that both LRR and gelsolin domains are required for the inhibitory effect of Fli-I on beta-catenin activity. Thus, FLAP1 enhanced LEF1/TCF-mediated transcription (Figure 1A) and beta-catenin dependent transcription (Figure 1B), while full-length Fli-I acted as a negative regulator of beta-catenin-dependent transcription (Figure 1B).
###end p 23
###begin title 24
siRNAs for FLAP1 inhibit LEF1/TCF mediated transcription
###end title 24
###begin p 25
###xml 162 171 162 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2A</xref>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 585 587 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 588 590 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 755 764 752 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2A</xref>
###xml 64 69 <span type="species:ncbi:9606">human</span>
Two siRNAs for FLAP1 (designed according to the sequence of the human ortholog LRRFIP1) efficiently reduced the level of endogenous FLAP1/LRRFIP1 in MCF-7 cells (Figure 2A, bottom panel). However, siRNAs for Fli-I, AIB1 and CARM1 did not affect the endogenous protein level of FLAP1. The siRNAs for Fli-I, AIB1 and CARM1 were previously demonstrated to cause reduced levels of the corresponding endogenous proteins (20). The roles of endogenous FLAP1 and Fli-I in transcription mediated by beta-catenin and LEF1/TCF were first tested in MCF-7 cells, which have elevated levels of Wnt (35,36). The LEF1/TCF-dependent TOPflash reporter plasmid had high basal activity in MCF-7 cells, but reduction of endogenous FLAP1 by siRNAs reduced TOPflash expression (Figure 2A, upper panel, bars 1-3). siRNA for AIB1 also suppressed TOPflash expression, but siRNAs for CARM1 and Fli-I had little effect (bars 4-6). Similar results were obtained in 293T cells or when a different LEF1/TCF-dependent reporter plasmid, pGL3OT-luc, was used (data not shown). These results suggest that endogenous FLAP1 is an essential coactivator for LEF1/TCF mediated transcription.
###end p 25
###begin title 26
Interaction of FLAP1 with beta-catenin and other coactivators
###end title 26
###begin p 27
###xml 117 126 114 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figures 1</xref>
###xml 131 132 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">2</xref>
###xml 254 263 251 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3A</xref>
###xml 284 292 281 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 616 618 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
Endogenous and exogenous FLAP1 has coactivator activity for beta-catenin mediated, LEF1/TCF dependent-transcription (Figures 1 and 2). To define molecular interactions that may contribute to these activities of FLAP1, GST-pulldown assays were performed (Figure 3A). FLAP1 synthesized in vitro bound to GST-fused beta-catenin, but not to GST-LEF1 and GST controls. FLAP1 also interacted with N- and C-terminus, but not with the middle region, of GRIP1. In contrast, the N-terminal LRR fragment of Fli-I bound to the GRIP1 N-terminal region but not to any of the other GST fusion proteins tested, as shown previously (20). Roughly equivalent levels of all the GST fusion proteins were loaded onto the glutathione-Sepharose beads, except that somewhat lower levels of GST-GRIP1M were used (Supplementary Figure 6A).
###end p 27
###begin p 28
###xml 139 140 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
Previously, Moon and colleagues showed that the C-terminal region of beta-catenin interacts with the KIX domain of CBP, a homolog of p300 (7). FLAP1 also interacted with p300 through the KIX domain but did not interact with the GRIP1 binding domain (GBD) of p300 or with GST (Supplementary Figure 6B).
###end p 28
###begin p 29
###xml 161 170 158 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3B</xref>
###xml 461 470 455 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3B</xref>
###xml 528 537 522 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3B</xref>
###xml 583 592 577 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3A</xref>
###xml 655 663 646 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
In co-immunoprecipitation assays, FLAP1 associated strongly with the C-terminal fragment of GRIP1 and weakly with the N-terminus of GRIP1 and with beta-catenin (Figure 3B, upper panel, lanes 3, 5 and 6). The relatively weak interactions observed may indicate that these proteins associate transiently rather than stably. However, FLAP1 did not interact with LEF1 (lane 7). The HA-tagged GRIP1 fragments, beta-catenin and LEF1 were expressed well in 293T cells (Figure 3B, lower panel). Thus, the co-immunoprecipitation results (Figure 3B) were consistent with the GST-pulldown data (Figure 3A), indicating that FLAP1 binds to GRIP1, beta-catenin and p300 in vitro and/or in mammalian cells. However, FLAP1 does not bind to LEF1, indicating that FLAP1 functions as a secondary coactivator for LEF1/TCF, i.e. the physical and functional interaction of FLAP1 with LEF1/TCF is mediated by one of the other coactivators.
###end p 29
###begin title 30
FLAP1 enhances the activities of two activation domains of GRIP1
###end title 30
###begin p 31
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 311 320 311 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3C</xref>
###xml 813 822 813 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2B</xref>
p300/CBP binds to and activates the middle domain of GRIP1, which contains AD1 (21). Since FLAP1 binds to both N- and C-termini of GRIP1, we tested the effects of FLAP1 and p300 on the three activation domains of GRIP1 fused to GAL4 DBD. The autonomous transcription activation activities of GRIP1N and GRIP1C (Figure 3C, bars 2) were further enhanced by the expression of FLAP1 (bars 3), but not by p300 (bars 4). In contrast, the autonomous activity of GRIP1M was enhanced by p300, but not by FLAP1. This shows that FLAP1 activates the activation domains in the N- and C-termini of GRIP1, while p300 activates AD1, located in the middle-domain of GRIP1. In support of these conclusions, siRNAs for FLAP1 specifically inhibited transcriptional activation by GRIP1N and GRIP1C, but not GRIP1M, fused to GAL4 DBD (Figure 2B, bars 3 and 4). Endogenous FLAP1 therefore has a selective role in mediating transcriptional activation by GRIP1N and C, but not by GRIP1M. Thus, FLAP1 binds to various coactivators including beta-catenin, GRIP1 and p300 and may contribute to the transcription-enhancing activity of beta-catenin by direct contact with one or more of these coactivators.
###end p 31
###begin title 32
Synergistic enhancement by FLAP1 and p300 of transcriptional activation by beta-catenin and LEF1/TCF or by androgen receptor
###end title 32
###begin p 33
###xml 105 114 102 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4A</xref>
###xml 381 390 372 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4B</xref>
###xml 710 719 695 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3A</xref>
###xml 805 814 790 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4C</xref>
FLAP1 and p300 independently enhanced the transcriptional activity of beta-catenin tethered to GAL4 DBD (Figure 4A, bars 3 and 4). However, when both FLAP1 and p300 were co-expressed, the beta-catenin-dependent transcription was synergistically activated (bar 5). In addition, FLAP1 and p300 independently enhanced LEF1/TCF-dependent transcription in the presence of beta-catenin (Figure 4B, bars 4-6). However, the co-expression of FLAP1, p300 and beta-catenin caused synergistic enhancement of LEF1/TCF mediated transcription (bar 8). The coactivator synergy of FLAP1 and p300 was not observed without the expression of beta-catenin (bar 7), consistent with our finding that FLAP1 does not bind to LEF1/TCF (Figure 3A). The synergy of FLAP1 and p300 was also observed in TOPflash reporter assay system (Figure 4C, bar 5), but not with FOPflash reporter (which has mutant TCF/LEF binding sites) (bar 10). This shows that the synergy of FLAP1 and p300 is dependent upon the binding of LEF1/TCF to DNA.
###end p 33
###begin p 34
###xml 384 393 384 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4D</xref>
###xml 1055 1057 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 96 121 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 123 127 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
The synergy of FLAP1 and p300 was also investigated in an AR-mediated transcription system. The mouse mammary tumor virus (MMTV)-luc reporter plasmid (which has binding sites for AR) was transfected into 293T cells along with an AR expression vector and the cells were treated with dihydrotestosterone (DHT). FLAP1 or p300 individually had little effect on AR-mediated transcription (Figure 4D, bars 3 and 4). However, when FLAP1 and p300 were expressed together, AR-mediated transcription was synergistically activated (bars 10 and 11) and this synergy was dependent on the co-expression of either beta-catenin or GRIP1 (bar 7). Thus, the combination of FLAP1 and p300 without beta-catenin or GRIP1 was not very effective in the activation of AR-mediated transcription. Thus, FLAP1 cooperates synergistically with p300 as a secondary coactivator for transcriptional activation by LEF1/TCF or AR, by binding to the primary coactivator beta-catenin or GRIP1. In spite of its dependence on GRIP1 or beta-catenin for its coactivator function with AR and ER (37), we found that FLAP1 did bind to at least some NRs. FLAP1 bound to estrogen receptor (ER) in a ligand-independent manner (Supplementary Figure 6C). However, over-expression of FLAP1 alone was not able to enhance transcriptional activation by either of the two activation domains of ER, AF1 or AF2, which were fused to GAL4 DBD (Supplementary Figure 6D). In contrast, the activities of both ERAF1 and ERAF2 were enhanced by the co-expression of p300.
###end p 34
###begin title 35
Fli-I inhibits the synergy of FLAP1 and p300
###end title 35
###begin p 36
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">32</xref>
###xml 235 244 232 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1B</xref>
###xml 338 346 335 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4</xref>
###xml 458 467 452 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5A</xref>
###xml 753 762 744 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5B</xref>
###xml 834 836 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 1615 1623 1603 1611 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1697 1705 1685 1693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Fli-I was previously characterized as a coactivator for NRs and Fli-I functions synergistically with GRIP1 and CARM1 as a coactivator for NRs (20). Since Fli-I also binds to FLAP1 (32) and inhibits beta-catenin mediated transcription (Figure 1B), we investigated the effect of Fli-I on the synergy of FLAP1 and p300. As previously shown (Figure 4), FLAP1 and p300 synergistically enhanced transcriptional activation by beta-catenin fused to GAL4 DBD (bar 8, Figure 5A). However, the coactivator synergy of FLAP1 and p300 was inhibited severely by co-transfection of increasing amounts of Fli-I expression vectors (lanes 9-13). The LRR and gelsolin-like fragments of Fli-I were less effective inhibitors of beta-catenin mediated transcription (bars 5-8, Figure 5B), although they are expressed at higher levels than full length Fli-I (20). This suggests that functions of both the LRR and gelsolin-like domains are required for the inhibitory activity of Fli-I. Thus, although Fli-I cooperates synergistically in GRIP1 coactivator complexes with NRs, Fli-I negatively regulates the activity of beta-catenin coactivator complexes. As an initial investigation of the mechanism of this negative regulation, we tested whether Fli-I fragments might inhibit binding of FLAP1 to p300. However, the LRR and Gelsolin-like fragments of Fli-I bound weakly or not at all to the p300 KIX domain (Supplementary Figure 6E and data not shown). We further tested whether the LRR and Gelsolin-like fragments of Fli-I could interfere with the binding of FLAP1 to the p300 KIX domain fused to GST. However, when 5-fold excess levels of in vitro translated LRR and Gelsolin-like fragments were mixed and incubated with in vitro translated FLAP1 and bead-bound GST-KIX, there was no reduction in binding of FLAP1 to the beads (Supplementary Figure 6F), suggesting that Fli-I does not interfere with the binding of FLAP1 to p300. Thus, the mechanism for the inhibitory effect of Fli-I on the coactivator function of beta-catenin, FLAP1 and p300 remains to be determined.
###end p 36
###begin title 37
DISCUSSION
###end title 37
###begin title 38
FLAP1 activates beta-catenin/LEF1/TCF-mediated transcription.
###end title 38
###begin p 39
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32">32</xref>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 520 529 517 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figures 1</xref>
###xml 534 535 531 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">2</xref>
###xml 683 691 677 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 20 25 <span type="species:ncbi:9606">human</span>
###xml 66 71 <span type="species:ncbi:9606">human</span>
FLAP1, its apparent human ortholog LRRFIP1 and another homologous human protein LRRFIP2 were originally identified as proteins that bind to the LRR domain of Fli-I (31,32). Another protein, TRIP, was identified as a TAR RNA binding protein and also has significant homology with FLAP1 (33). However, the functional roles of FLAP1 and the other Fli-LRR interacting molecules are not well characterized. The current study shows that FLAP1 is required for efficient transcriptional activation by beta-catenin and LEF1/TCF (Figures 1 and 2). FLAP1 acts as a coactivator by binding to the activation domains of other coactivators like GRIP1 and beta-catenin and enhancing their activity (Figure 3).
###end p 39
###begin p 40
###xml 95 97 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 394 396 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 167 174 <span type="species:ncbi:8355">Xenopus</span>
###xml 429 434 <span type="species:ncbi:10090">mouse</span>
###xml 483 488 <span type="species:ncbi:9606">human</span>
Recently, LRRFIP2 was shown to be a strong activator for beta-catenin dependent transcription (38) and a dominant negative form of LRRFIP2 suppressed Wnt signaling in Xenopus. This is consistent with our data showing an important role for FLAP1 in beta-catenin dependent transcription. LRRFIP2 interacts with Dvl (disheveled) and activates the cytoplasmic part of the Wnt/beta-catenin pathway (38). However, our study shows that mouse FLAP1 (and therefore presumably the orthologous human LRRFIP1) binds to nuclear proteins like GRIP1 and p300 and cooperates with these coactivators to enhance transcriptional activation by beta-catenin and its associated DNA-binding transcription factors. Thus, it is possible that FLAP1 may activate the Wnt/beta-catenin pathway at both the cytoplasmic and nuclear levels. Since FLAP1 and LRRFIP2 are 58% identical in amino acid sequence (by comparison of GenBank accession numbers AAC40072 and AAD41257), FLAP1 may also interact with Dvl and activate the cytoplasmic pathway of beta-catenin. On the other hand, it is possible that FLAP1 may have a unique mechanism, which is different from that of LRRFIP2. For example, FLAP1 may primarily act inside the nucleus and LRRFIP2 in the cytoplasm, such that they contribute in a complementary way to regulation of Wnt/beta-catenin signaling. Thus, FLAP1, LRRFIP1, LRRFIP2 and TRIP may comprise a family of proteins, which regulate Wnt/beta-catenin signaling through a variety of mechanisms.
###end p 40
###begin p 41
###xml 152 160 149 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5</xref>
###xml 251 253 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 254 256 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 257 259 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 546 554 537 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1563 1572 1545 1554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5C</xref>
This study also suggests that FLAP1 cooperates with p300 for the activation of beta-catenin dependent, LEF1/TCF mediated and AR-mediated transcription (Figure 5). This is reminiscent of the synergy of CARM1 and p300 or the synergy of CARM1 and Fli-I (11,20,24). The synergy of all these secondary coactivators, including FLAP1, requires the co-expression of a primary coactivator, such as GRIP1 or beta-catenin. GRIP1 or beta-catenin may act as a bridge factor for stabilizing the coactivator complex, although FLAP1 interacts directly with p300 in vitro (Supplementary Figure 6). Alternatively, by associating directly with the DNA bound transcription factor (LEF1/TCF or NR), GRIP1 and beta-catenin may provide a platform for recruiting FLAP1 and p300 to the promoter. GRIP1 and beta-catenin may have overlapping or complementary roles in promoting the synergistic action of FLAP1 and p300. FLAP1 shows a unique pattern of coactivator binding and transcription activation, which is distinguished from p300 and other coactivators. FLAP1, p300 and CARM1 bind to different ADs of GRIP1 and presumably transmit output signals to different downstream targets in the transcription machinery, thus accounting for their synergistic cooperation. The fact that FLAP1 and p300 together interact with all three ADs of GRIP1 may explain why this combination of coactivators yields such a strong synergy with GRIP1 and beta-catenin. Overall, our results suggest that FLAP1 may be an essential partner molecule which cooperates with p300 to mediate the Wnt signaling pathway (Figure 5C).
###end p 41
###begin title 42
Implications of inhibitory roles of Fli-I in beta-catenin mediated transcription and Wnt/Wingless signaling
###end title 42
###begin p 43
###xml 236 238 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 338 340 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 636 645 624 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5C</xref>
###xml 1273 1282 1252 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figures 1</xref>
###xml 1287 1288 1266 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">5</xref>
###xml 1543 1545 1522 1524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 1546 1548 1525 1527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 1705 1707 1681 1683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 1768 1776 1741 1749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5</xref>
###xml 2702 2703 2663 2664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 2704 2705 2665 2666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 2706 2708 2667 2669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
Fli-I was originally identified as an essential protein for the development of Drosophila and mouse. Since Fli-I, like beta-catenin, is associated with the actin cytoskeleton in the cytoplasm and shuttles between nucleus and cytoplasm (29), the possible involvement of Fli-I in the beta-catenin/LEF1/TCF pathway was previously suggested (20). Here, we demonstrated that, in addition to its previously identified coactivator function with NRs, Fli-I has important roles in the regulation of the beta-catenin/LEF1/TCF mediated pathway. Fli-I suppresses beta-catenin/LEF1/TCF mediated transcription, whereas FLAP1 has the opposite effect (Figure 5C). Our initial studies on the negative regulation of beta-catenin-p300-FLAP1 activity by Fli-I found that Fli-I does not bind well to p300 KIX domain and does not appear to inhibit FLAP1-p300 binding (Supplementary Figure 6E and F). Fli-I may exert its negative influence by squelching the activity of FLAP1 and other essential factors that bind to Fli-I. It is also possible that Fli-I may recruit negative regulators, such as HDACs, CtBP, Groucho and Chibby, to the beta-catenin/LEF1/TCF transcription complex. Both the LRR and gelsolin-like domains of Fli-I are required for the negative regulation of beta-catenin function (Figures 1 and 5). However, while the LRR domain binds to FLAP1, the inhibitory mechanisms of the gelsolin-like domain are less clear. Some of the interactions of the gelsolin domain, i.e. with BAF53 (a component of the Swi/Snf complex), CARM1, actin and other proteins (20,29), may provide clues to the mechanism by which Fli-I inhibits beta-catenin mediated transcription. Since Fli-I acts positively on NR-mediated transcription (20) and negatively on beta-catenin/LEF1/TCF mediated function (Figure 5), Fli-I may help to determine the balance between NR and beta-catenin/LEF1/TCF activity. Increased nuclear levels of Fli-I would presumably favor NR-mediated transcription, while lowered nuclear levels of Fli-I or increased FLAP1 levels would probably result in the release of FLAP1 and support the activation of beta-catenin/LEF1/TCF-mediated transcription through the synergy of FLAP1 and p300. Thus, Fli-I and FLAP1 have antagonistic roles in the regulation of beta-catenin/LEF1/TCF mediated transcription and may play key roles in the regulation of the Wnt/Wingless-signaling pathway. In addition, interactions of Fli-I and FLAP1 with other proteins may also be crucial for the regulation of these pathways. It follows that mutations in Fli-I may result in dysregulation of the beta-catenin pathway and Wnt/Wingless-signaling and thus may account for the previously reported developmental abnormalities of Fli-I mutants (1,2,25). Furthermore, the opposing roles of FLAP1 and Fli-I may have significance for the process of carcinogenesis. Since beta-catenin over-expression is important in many cancers, FLAP1 and Fli-I may play roles as oncogene and tumor suppressor, respectively.
###end p 43
###begin title 44
SUPPLEMENTARY DATA
###end title 44
###begin p 45
Supplementary Data are available at NAR Online.
###end p 45
###begin title 46
Supplementary Material
###end title 46
###begin title 47
[Supplementary Data]
###end title 47
###begin p 48
We thank Dr Helen L. Yin (University of Texas Southwestern) for providing a plasmid encoding FLAP1 and D. Gerke (University of Southern California) for his technical assistance. This work was supported by United States Public Health Service grant DK43093 (M.R.S) from the National Institutes of Health. Funding to pay the Open Access publication charges for this article was provided by NIH grant DK43093.
###end p 48
###begin p 49
###xml 0 31 0 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement.</italic>
Conflict of interest statement. None declared.
###end p 49
###begin title 50
REFERENCES
###end title 50
###begin article-title 51
Caught up in a Wnt storm: Wnt signaling in cancer
###end article-title 51
###begin article-title 52
Beta-catenin signaling and cancer
###end article-title 52
###begin article-title 53
Balancing cell adhesion and Wnt signaling, the key role of beta-catenin
###end article-title 53
###begin article-title 54
Beta-catenin-histone deacetylase interactions regulate the transition of LEF1 from a transcriptional repressor to an activator
###end article-title 54
###begin article-title 55
Curbing the nuclear activities of beta-catenin. Control over Wnt target gene expression
###end article-title 55
###begin article-title 56
Regulation of beta -catenin transformation by the p300 transcriptional coactivator
###end article-title 56
###begin article-title 57
The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression
###end article-title 57
###begin article-title 58
The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation
###end article-title 58
###begin article-title 59
Synergistic effects of coactivators GRIP1 and beta-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways
###end article-title 59
###begin article-title 60
Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription
###end article-title 60
###begin article-title 61
Synergistic coactivator function by coactivator-associated arginine methyltransferase (CARM) 1 and beta-catenin with two different classes of DNA-binding transcriptional activators
###end article-title 61
###begin article-title 62
###xml 53 60 <span type="species:ncbi:8355">Xenopus</span>
XCtBP is a XTcf-3 co-repressor with roles throughout Xenopus development
###end article-title 62
###begin article-title 63
Drosophila Tcf and Groucho interact to repress Wingless signalling activity
###end article-title 63
###begin article-title 64
Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors
###end article-title 64
###begin article-title 65
###xml 4 11 <span type="species:ncbi:8355">Xenopus</span>
The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors
###end article-title 65
###begin article-title 66
Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless pathway
###end article-title 66
###begin article-title 67
The role of the androgen receptor in the development and progression of prostate cancer
###end article-title 67
###begin article-title 68
Beta-catenin affects androgen receptor transcriptional activity and ligand specificity
###end article-title 68
###begin article-title 69
Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300
###end article-title 69
###begin article-title 70
Developmentally essential protein flightless I is a nuclear receptor coactivator with actin binding activity
###end article-title 70
###begin article-title 71
The roles of protein-protein interactions and protein methylation in transcriptional activation by nuclear receptors and their coactivators
###end article-title 71
###begin article-title 72
Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53
###end article-title 72
###begin article-title 73
Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-kappaB-dependent gene expression
###end article-title 73
###begin article-title 74
Synergy among nuclear receptor coactivators: selective requirement for protein methyltransferase and acetyltransferase activities
###end article-title 74
###begin article-title 75
###xml 4 27 4 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila melanogaster</italic>
###xml 4 27 <span type="species:ncbi:7227">Drosophila melanogaster</span>
###xml 169 191 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
###xml 196 202 <span type="species:ncbi:9606">humans</span>
The Drosophila melanogaster flightless-I gene involved in gastrulation and muscle degeneration encodes gelsolin-like and leucine-rich repeat domains and is conserved in Caenorhabditis elegans and humans
###end article-title 75
###begin article-title 76
###xml 28 51 28 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila melanogaster</italic>
###xml 28 51 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Mammalian homologues of the Drosophila melanogaster flightless I gene involved in early development
###end article-title 76
###begin article-title 77
###xml 27 50 27 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila melanogaster</italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 27 50 <span type="species:ncbi:7227">Drosophila melanogaster</span>
The human homologue of the Drosophila melanogaster flightless-I gene (flil) maps within the Smith-Magenis microdeletion critical region in 17p11.2
###end article-title 77
###begin article-title 78
The flightless I protein localizes to actin-based structures during embryonic development
###end article-title 78
###begin article-title 79
The flightless I protein colocalizes with actin- and microtubule-based structures in motile Swiss 3T3 fibroblasts: evidence for the involvement of PI 3-kinase and Ras-related small GTPases
###end article-title 79
###begin article-title 80
The leucine-rich repeat as a protein recognition motif
###end article-title 80
###begin article-title 81
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 103 108 <span type="species:ncbi:4932">yeast</span>
Novel proteins interacting with the leucine-rich repeat domain of human flightless-I identified by the yeast two-hybrid system
###end article-title 81
###begin article-title 82
Identification of the binding partners for flightless I, A novel protein bridging the leucine-rich repeat and the gelsolin superfamilies
###end article-title 82
###begin article-title 83
TRIP: a novel double stranded RNA binding protein which interacts with the leucine rich repeat of flightless I
###end article-title 83
###begin article-title 84
Regulation of coactivator complex assembly and function by protein arginine methylation and demethylimination
###end article-title 84
###begin article-title 85
###xml 66 71 <span type="species:ncbi:9606">human</span>
An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells
###end article-title 85
###begin article-title 86
###xml 49 54 <span type="species:ncbi:9606">human</span>
Redundant expression of canonical Wnt ligands in human breast cancer cell lines
###end article-title 86
###begin article-title 87
###xml 49 56 49 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Wnt/beta-catenin and estrogen signaling converge in vivo
###end article-title 87
###begin article-title 88
Identification of the Wnt signaling activator leucine-rich repeat in flightless interaction protein 2 by a genome-wide functional analysis
###end article-title 88
###begin title 89
Figures and Tables
###end title 89
###begin p 90
###xml 76 77 73 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 275 276 266 267 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
FLAP1 and Fli-I regulate beta-catenin and LEF1/TCF-mediated transcription. (A) Reporter plasmid pGL3OT-luc (0.2 mug) was transfected into 293T cells in 12-well dishes along with pSG5-betaCAT (0.2 mug) and pCMV-FLAP1, pSG5.HA-GRIP1 or pcDNA-Fli-I (0.2-0.6 mug) as indicated. (B) Reporter plasmid GK1-Luc (0.2 mug) was transfected into 293T cells with 0.2 mug of each of the following plasmids, as indicated: pM-beta-catenin, pCMV-FLAP1, pcDNA-Fli-I, pSG5-Fli-LRR, pSG5-Fli-Gelsolin.
###end p 90
###begin p 91
###xml 87 88 87 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 448 449 446 447 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Inhibition of LEF1/TCF-mediated and GRIP1-mediated transcription by siRNAs for FLAP1. (A) TOPflash reporter plasmid (0.5 mug) was transfected into MCF-7 cells in 12-well dishes along with 50 pmol of siRNA for FLAP1, Fli-I, AIB1 or CARM1. Luciferase activity was measured at 40 h (top panel) and part of each cell extract was analyzed by immunoblot with 1 mug of anti-FLAP1 antibody to monitor the endogenous level of FLAP1 protein (bottom panel). (B) GK1 reporter plasmid (0.2 mug) was transfected into 293T cells along with pM-GRIP1N, pM-GRIP1M or pM-GRIP1C (0.2 mug) and 50 pmol of siRNAs for FLAP1.
###end p 91
###begin p 92
###xml 64 65 61 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 87 95 84 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 330 331 314 315 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1007 1008 986 987 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
Interaction of FLAP1 with beta-catenin and other coactivators. (A) GST-pulldown assay: in vitro translated FLAP1 protein or Fli-I LRR fragment was incubated with purified GST fusion proteins (approximately1 mug) bound to glutathione-Sepharose beads. Bound protein fractions were analyzed by immunoblot with anti-Flag antibodies. (B) Co-immunoprecipitation assay: 2 mug of expression vectors pCMV-flag-FLAP1, pSG5.HA.GRIP1N, pSG5.HA.GRIP1M, pSG5.HA.GRIP1C, pSG5.HA.beta-catenin and pSG5.HA.LEF1 were transfected into 293T cells as indicated. After 40 h, transfected cells were collected and lysed with RIPA buffer. Two percent of cell extracts were loaded into a separate gel for loading control and analyzed by immunoblot with anti-HA antibody (lower panel). One microgram of anti-Flag antibody was added to the remaining extract with protein A/G agarose beads. Anti-HA antibody (0.2 mug of antibody per 1 ml of blocking buffer) was used to detect the co-precipitated proteins by immunoblot (upper panel). (C) Mammalian one hybrid assay: 0.2 mug of GK1-Luc, pM-GRIP1N, pM-GRIP1M and pM-GRIP1C were transfected along with 0.2 mug of pCMV-FLAP1 and pCMV-p300 vectors as indicated.
###end p 92
###begin p 93
###xml 107 108 104 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 305 306 301 302 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 557 558 552 553 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 795 796 789 790 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 868 872 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Synergy of FLAP1 and p300 for enhancement of transcriptional activation by beta-catenin, LEF1/TCF and AR. (A) Mammalian one hybrid assay was performed as follows: GK1-Luc, pCMV-FLAP1 and pCMV-p300 (0.2 mug of each) were transfected into 293T cells as indicated. Luciferase activity was measured at 40 h. (B) LEF1/TCF-dependent transient transfection assay was performed with pGL3OT-luc reporter plasmid as follows: pGL3OT-luc, pCMV-FLAP1, pCMV-p300, pSG5-bCAT, pSG5.HA-GRIP1 and pcDNA-Fli-I (0.2 mug of each as indicated) were transfected into 293T cells. (C) LEF1/TCF-dependent transient transfection assay was performed with TOP/FOP reporter plasmids as follows: TOPflash-luc, FOPflash-luc, pCMV-FLAP1, pCMV-p300 and pSG5-bCAT (0.2 mug of each as indicated) were transfected into 293T cells. (D) AR-dependent transient transfection assays were performed as follows: MMTV-luc, pCMV-FLAP1, pCMV-p300, pSG5-beta-catenin and pSG5.HA-GRIP1 (0.2 mug of each as indicated) and 10 ng of AR expression vector were transfected into 293T cells. 100 muM of DHT was added after transfection.
###end p 93
###begin p 94
###xml 47 48 47 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 55 56 55 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 365 366 358 359 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
Fli-I inhibits the synergy of FLAP1 and p300. (A) and (B). Mammalian one hybrid assay: GK1-Luc, pM-beta-catenin, pCMV-FLAP1, pCMV-p300, pSG5-LRR, pSG5-Gelsolin (0.1 mug of each as indicated), were transfected into 293T cells. Variable amounts of Fli-I expression vectors were used: A, bar 5: 0.1 mug; Bars 9-13: 0.2, 0.1, 0.05, 0.025, 0.01 mug. B, bar 6: 0.1 mug. (C) Model: Interplay of Fli-I and FLAP1 for regulating beta-catenin mediated gene expression. beta-catenin is translocated into the nucleus and interacts with LEF1/TCF to activate transcription. beta-catenin recruits other coregulators to modulate LEF1/TCF-mediated transcription. beta-catenin interacts with FLAP1, p300 and GRIP1 to activate transcription synergistically. However, elevated levels of Fli-I protein shut down FLAP1-dependent beta-catenin/LEF1/TCF mediated transcription activation.
###end p 94

